VANCOUVER, May 19 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI, TSX: ANP) today announced that its corporate partner, Boston Scientific Corporation (NYSE: BSX) has launched the platinum chromium TAXUS(R) Element(TM) Paclitaxel-Eluting Coronary Stent System in select markets worldwide. The TAXUS Element Stent features a new platinum chromium alloy engineered specifically for coronary stent applications and represents the Company's third-generation drug-eluting stent (DES) technology.
The TAXUS Element Stent is built on the advanced platinum chromium platform and is designed to provide interventional cardiologists improved performance in treating patients with complex coronary artery disease. Boston Scientific has reported that it anticipates CE Mark approval for the TAXUS Element Stent in the fourth quarter of this year.
"Boston Scientific continues to make significant progress toward improving the performance of TAXUS stents," said Dr. William Hunter, President and CEO of Angiotech. "The launch of this third-generation TAXUS stent demonstrates the efficacy and longevity of the paclitaxel platform in treating patients with heart disease."
The platinum chromium alloy used in the Element Stent System was engineered specifically for coronary stenting, delivering both strength and flexibility. The Element Stent System platform also features a new stent architecture with thinner struts, increased flexibility and a lower profile, designed to improve radial strength, recoil and angiographic visibility. Deliverability to complex lesions is further enhanced through the incorporation of a new highly deliverable dilatation catheter technology.
"Our platinum chromium Element Stent series represents a significant leap forward in
|SOURCE Angiotech Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved